Add to a list

Inactive Instrument

LOTUS PHARM Stock OTC Bulletin Board

LTUS

US5457151042

Pharmaceuticals

OTC Markets Traded

End-of-day quote OTC Bulletin Board
- ^USD	-

31/07/23	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
26/11/21	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE

Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

As early as today, start finding the best investment opportunities!

Market Cap	9.74M 8.69M 8.03M 7.28M 13.62M 924M 13.84M 96.65M 38.26M 484M 36.54M 35.76M 1.53B	P/E 2009	3.88x	P/E 2010	4.84x
Enterprise Value	14.38M 12.84M 11.86M 10.75M 20.12M 1.37B 20.45M 143M 56.53M 715M 53.98M 52.83M 2.26B	EV / Sales 2009	1.02x	EV / Sales 2010	0.95x
Free-Float	99%	Yield 2009 *	-	Yield 2010	-

31/07/23	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
26/11/21	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE
28/09/21	Lotus Pharmaceuticals : Temasek-backed Vertex expects at least $400 million in new S.E.Asia/India fund	RE
16/05/12	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS from LTUSE	CI
19/04/12	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS.E from LTUS	CI

12-30	Lotus Pharmaceutical Supports Street Medicine Program to Expand Access to Care for Those Most in Need	AQ
06/10/25	Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection	AQ
12/08/25	Lotus Pharmaceutical Achieves New First-Half Record in Revenue for 2025, While Q2 Impacted by FX and Timing of Lenalidomide Sales	AQ
21/02/25	Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis	AQ
08/11/24	Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-3.04%	+0.81%	+54.34%	+119.75%	1,165B
JOHNSON & JOHNSON	-1.40%	+3.22%	+37.06%	+74.25%	645B
ABBVIE INC.	+0.23%	+0.01%	+25.06%	+97.23%	504B
ROCHE HOLDING AG	-0.31%	+3.09%	+43.92%	+64.55%	380B
MERCK & CO., INC.	-1.58%	-0.58%	+66.44%	+40.40%	363B
NOVARTIS AG	-0.68%	+2.65%	+22.46%	+51.48%	297B
ASTRAZENECA PLC	-1.20%	+3.04%	+2.62%	+26.97%	269B
AMGEN INC.	-1.68%	+1.88%	+50.44%	+61.37%	237B
GILEAD SCIENCES, INC.	-0.21%	+0.42%	+29.90%	+102.22%	195B
Average	-1.16%	+2.54%	+36.92%	+70.91%	450.61B
Weighted average by Cap.	-1.54%	+3.17%	+40.89%	+82.02%

	2009	2010
Net sales	57.82M 51.64M 47.7M 43.23M 80.88M 5.49B 82.22M 574M 227M 2.88B 217M 212M 9.07B	72.7M 64.92M 59.97M 54.35M 102M 6.9B 103M 722M 286M 3.62B 273M 267M 11.4B
Net income	16.43M 14.67M 13.56M 12.28M 22.98M 1.56B 23.36M 163M 64.58M 817M 61.67M 60.36M 2.58B	14.42M 12.88M 11.9M 10.78M 20.18M 1.37B 20.51M 143M 56.69M 717M 54.14M 52.98M 2.26B
Net Debt	5.29 4.73 4.37 3.96 7.4 502.54 7.53 52.55 20.81 263.3 19.87 19.44 830.11	4.65 4.15 3.83 3.47 6.5 441.11 6.61 46.13 18.26 231.11 17.44 17.07 728.64

LOTUS PHARM Stock OTC Bulletin Board

Stocks

LTUS

US5457151042

Pharmaceuticals

Valuation: LOTUS PHARM

Latest news: LOTUS PHARM

Press Releases: LOTUS PHARM

Managers and Directors: LOTUS PHARM

Generic Pharmaceuticals

Financials

Company Profile